AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31573644 — intervention group
Group type: COMPARATOR
Intervention: Traditional clinical instruction in control group
Number of subjects: 586
Study 28217868 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecamylamine 10 mg
Number of subjects: 12
Study 28217868 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecamylamine 20 mg
Number of subjects: 12
Study 28217868 — intervention group
Group type: COMPARATOR
Intervention: Scopolamine 0.5 mg
Number of subjects: 12
Study 28217868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 25872301 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant anchorage
Number of subjects: 46
Study 25872301 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraoral anchorage
Number of subjects: 46
Study 25872301 — intervention group
Group type: EXPERIMENTAL
Intervention: Nance arch anchorage
Number of subjects: 46
Study 24649784 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 90
Study 24649784 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal intubation (ETT)
Number of subjects: 90
Study 21496949 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer hydrochloride (800 mg by mouth three times daily)
Number of subjects: 40
Study 21496949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 18779378 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinaciguat (50-250 microg/h) administered intravenously for up to 4 hours
Number of subjects: 76
Study 18779378 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinaciguat (150-250 microg/h) administered intravenously for up to 4 hours
Number of subjects: 76
Study 18779378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 16813911 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 nM resiniferatoxin
Number of subjects: 54
Study 16813911 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (10% ethanol in normal saline)
Number of subjects: 54
Study 15220787 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia plus epidural fentanyl and lidocaine before incision (group 1)
Number of subjects: 141
Study 15220787 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia plus epidural fentanyl and lidocaine after incision (group 2)
Number of subjects: 141
Study 15220787 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia plus a sham epidural (group 3)
Number of subjects: 141
Study 15220787 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 141
Study 11099083 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day intramuscular ceftriaxone (50 mg/kg)
Number of subjects: 109
Study 11099083 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day intramuscular ceftriaxone (50 mg/kg/day)
Number of subjects: 109
Study 9495995 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological suggestion therapy
Number of subjects: 120
Study 9495995 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous birth processes (Control)
Number of subjects: 120
Study 8394842 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Seleparina, CY 216) administered as 2 x 3,825 anti‐Xa international units subcutaneously on the day of surgery followed by a single daily 3,825 anti‐Xa international units injection for 7 days.
Number of subjects: 61
Study 8394842 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylaxis).
Number of subjects: 61
Study 8394842 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Seleparina, CY 216).
Number of subjects: 61
Study 2941473 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants (active medication)
Number of subjects: 15
Study 2941473 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 15
Study 29754651 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 830
Study 26880010 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional NAM treatment (Group 1, n = 6)
Number of subjects: 12
Study 26880010 — intervention group
Group type: COMPARATOR
Intervention: CAD/CAM NAM (Group 2, n = 6)
Number of subjects: 12
Study 24129264 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based smoking intervention program lasting one year
Number of subjects: 0
Study 24129264 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 22301075 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Number of subjects: 100
Study 22301075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 22301075 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide (in patients with Giardia lamblia)
Number of subjects: 100
Study 22301075 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide (in patients with no identified enteropathogen)
Number of subjects: 100
Study 20483885 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine 10 mg twice a day (4 week titration followed by 12 weeks on the highest tolerated dose)
Number of subjects: 0
Study 20483885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18395902 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG)
Number of subjects: 62
Study 18395902 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis ssp. lactis Bb12 (Bb12)
Number of subjects: 62
Study 18395902 — intervention group
Group type: EXPERIMENTAL
Intervention: Propionibacterium freudenreichii ssp. shermanii JS (PJS)
Number of subjects: 62
Study 18395902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 15814016 — intervention group
Group type: EXPERIMENTAL
Intervention: Biannual guaiac-based FOB test with three test cards for consecutive samples
Number of subjects: 20000
Study 15814016 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-invited individuals)
Number of subjects: 20000
Study 12417389 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 170
Study 12417389 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 170
Study 12417389 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 170
Study 10065817 — intervention group
Group type: EXPERIMENTAL
Intervention: Omentoplasty (OP)
Number of subjects: 115
Study 10065817 — intervention group
Group type: COMPARATOR
Intervention: Not performing Omentoplasty (NO)
Number of subjects: 115
Study 7554206 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flow cardiopulmonary bypass
Number of subjects: 171
Study 7554206 — intervention group
Group type: COMPARATOR
Intervention: Circulatory arrest
Number of subjects: 171
Study 7554206 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flow cardiopulmonary bypass and Circulatory arrest
Number of subjects: 171
Study 2404841 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (20 mg/m2 day 1 and 8) in combination with PCOP regimen (cyclophosphamide 400 mg/m2 day 1 and 8, vincristine 1.4 mg/m2 day 1 and 8, procarbazine 80 mg/m2 day 1 to 14, prednisone 60 mg/m2 day 1 to 5)
Number of subjects: 113
Study 2404841 — intervention group
Group type: COMPARATOR
Intervention: PCOP regimen without doxorubicin
Number of subjects: 113
Study 2404841 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (20 mg/m2 day 1 and 8)
Number of subjects: 113
Study 6776543 — intervention group
Group type: EXPERIMENTAL
Intervention: Mazindol (2 mg or occasionally 4 mg/day)
Number of subjects: 95
Study 6776543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 31488360 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomustine-temozolomide (100 mg/m2 on day 1 plus 100-200 mg/m2 on days 2-6 for six 6-week courses)
Number of subjects: 141
Study 31488360 — intervention group
Group type: COMPARATOR
Intervention: Temozolomide (75 mg/m2 daily during radiotherapy plus six 4-week courses of temozolomide [150-200 mg/m2] on days 1-5)
Number of subjects: 141
Study 31488360 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomustine-temozolomide
Number of subjects: 141
Study 28160217 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone 0.5 mg
Number of subjects: 340
Study 28160217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study 25872890 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve-sparing radical hysterectomy (NSRH)
Number of subjects: 86
Study 25872890 — intervention group
Group type: COMPARATOR
Intervention: Conventional radical hysterectomy (CRH)
Number of subjects: 86
Study 24088835 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin composite crowns with fiber-reinforced framework
Number of subjects: 66
Study 24088835 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin composite crowns without fiber-reinforced framework
Number of subjects: 66
Study 24088835 — intervention group
Group type: COMPARATOR
Intervention: Metal-ceramic crowns
Number of subjects: 66
Study 21461891 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivanib alaninate (800 mg) in fasting state
Number of subjects: 0
Study 21461891 — intervention group
Group type: COMPARATOR
Intervention: Brivanib alaninate (800 mg) following ingestion of a high-fat meal
Number of subjects: 0
Study 21461891 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivanib alaninate (800 mg) once daily until discontinuation (multiple doses)
Number of subjects: 0
Study 19158659 — intervention group
Group type: EXPERIMENTAL
Intervention: Training arm and hand together
Number of subjects: 8
Study 19158659 — intervention group
Group type: COMPARATOR
Intervention: Training arm and hand separately
Number of subjects: 8
Study 19158659 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual mirror feedback
Number of subjects: 8
Study 17370489 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-pricking therapy
Number of subjects: 121
Study 17370489 — intervention group
Group type: COMPARATOR
Intervention: Medication (domiphen and HCG)
Number of subjects: 121
Study 15548313 — intervention group
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine
Number of subjects: 108
Study 15548313 — intervention group
Group type: COMPARATOR
Intervention: artesunate-mefloquine
Number of subjects: 108
Study 11837987 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid, alone or in combination with vitamin B12 and vitamin B6
Number of subjects: 0
Study 11837987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9522322 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin (100 IU/day) with calcium supplementation (1000 mg/day)
Number of subjects: 38
Study 9522322 — intervention group
Group type: COMPARATOR
Intervention: Calcium supplementation (1000 mg/day) with placebo intranasal spray
Number of subjects: 38
Study 9522322 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin (100 IU/day)
Number of subjects: 38
Study 8425809 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical clindamycin lotion applied twice daily
Number of subjects: 43
Study 8425809 — intervention group
Group type: COMPARATOR
Intervention: Oral tetracycline (250 mg four times a day for 3 weeks, then 250 mg twice a day for the remaining 9 weeks)
Number of subjects: 43
Study 3675694 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 1000 mg + ambroxol 60 mg t.i.d. (n = 8)
Number of subjects: 16
Study 3675694 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin 1000 mg t.i.d. (n = 8)
Number of subjects: 16
Study 2649400 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin
Number of subjects: 100
Study 2649400 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin/Metronidazole
Number of subjects: 100
Study 4950563 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholera vaccine
Number of subjects: 0
Study 4950563 — intervention group
Group type: COMPARATOR
Intervention: Typhoid vaccine (control)
Number of subjects: 0
Study 4950563 — intervention group
Group type: EXPERIMENTAL
Intervention: Unvaccinated group
Number of subjects: 0
Study 31401085 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 640
Study 31401085 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (AZT)
Number of subjects: 640
Study 31401085 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight <48 kg
Number of subjects: 640
Study 31401085 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight 48-59.9 kg
Number of subjects: 640
Study 31401085 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 640
Study 28362032 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided blocks (U group)
Number of subjects: 109
Study 28362032 — intervention group
Group type: COMPARATOR
Intervention: Peripheral nerve stimulator-confirmed blocks (N group)
Number of subjects: 109
Study 28362032 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided and peripheral nerve stimulator-confirmed blocks (dual guidance; NU group)
Number of subjects: 109
Study 25308804 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer and stronger post-induction therapy for T cell ME WBC patients
Number of subjects: 251
Study 25308804 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment for B-ALL ME WBC patients
Number of subjects: 251
Study 25308804 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment for patients with WBC <200 × 10(9) /l
Number of subjects: 251
Study 23058230 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 60
Study 23058230 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 60
Study 21666574 — intervention group
Group type: EXPERIMENTAL
Intervention: Group rehabilitation (GrpR) for 15 days (T1) followed by individual rehabilitation (IndR) for 15 days (T2)
Number of subjects: 27
Study 21666574 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual rehabilitation (IndR) for 15 days (T1) followed by group rehabilitation (GrpR) for 15 days (T2)
Number of subjects: 27
Study 20082252 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming moxibustion on Shenque acupoint (RN8)
Number of subjects: 60
Study 20082252 — intervention group
Group type: COMPARATOR
Intervention: Smecta (control group)
Number of subjects: 60
Study 17416007 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (Dex) plus Ginsenosides (GS)
Number of subjects: 120
Study 17416007 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (Dex)
Number of subjects: 120
Study 17416007 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginsenosides (GS)
Number of subjects: 120
Study 17416007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 15610309 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine and IFN-alpha (LAM/IFN)
Number of subjects: 83
Study 15610309 — intervention group
Group type: COMPARATOR
Intervention: lamivudine only (LAM)
Number of subjects: 83
Study 11502614 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Education (PE) - 7 x 30 minute one to one sessions
Number of subjects: 100
Study 11502614 — intervention group
Group type: COMPARATOR
Intervention: Standard management (Control Group)
Number of subjects: 100
Study 9229231 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray (NNS)
Number of subjects: 10
Study 9229231 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking four cigarettes
Number of subjects: 10
Study 9229231 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 10
Study 8389406 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid diet with soluble fiber (21 g/L)
Number of subjects: 12
Study 8389406 — intervention group
Group type: COMPARATOR
Intervention: Liquid diet without soluble fiber
Number of subjects: 12
Study 8389406 — intervention group
Group type: COMPARATOR
Intervention: Self-selected diet
Number of subjects: 12
Study 8389406 — intervention group
Group type: EXPERIMENTAL
Intervention: Both liquid diets
Number of subjects: 12
Study 8389406 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting cholecystokinin concentrations
Number of subjects: 12
Study 2831114 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg once daily, doubled if BP not controlled after 4 weeks
Number of subjects: 174
Study 2831114 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 12.5 mg once daily, doubled if BP not controlled after 4 weeks
Number of subjects: 174
Study 2831114 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 174
Study 2831114 — intervention group
Group type: COMPARATOR
Intervention: HCTZ
Number of subjects: 174
Study 30903459 — intervention group
Group type: COMPARATOR
Intervention: Low molecular weight heparin (LMWH), Fraxiparine (0.4 ml, 3800 IU/day) for 2 days
Number of subjects: 74
Study 30903459 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rivaroxaban 10 mg/day for 2 days
Number of subjects: 74
Study 30903459 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rivaroxaban 20 mg/day for 2 days
Number of subjects: 74
Study 28356142 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg (400 IU) of vitamin D3 supplementation
Number of subjects: 0
Study 28356142 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 μg (1200 IU) of vitamin D3 supplementation
Number of subjects: 0
Study 27004303 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol TCI
Number of subjects: 75
Study 27004303 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 75
Study 27004303 — intervention group
Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 75
Study 23291602 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistive technology intervention
Number of subjects: 44
Study 23291602 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention group
Number of subjects: 44
Study 20473229 — intervention group
Group type: EXPERIMENTAL
Intervention: Trekking poles (TP)
Number of subjects: 37
Study 20473229 — intervention group
Group type: COMPARATOR
Intervention: No poles (NP)
Number of subjects: 37
Study 18275558 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (400 mg)
Number of subjects: 21
Study 18275558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 16489972 — intervention group
Group type: EXPERIMENTAL
Intervention: GlucoWatch G2 Biographer (GW2B)
Number of subjects: 200
Study 16489972 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) using a conventional home glucose meter
Number of subjects: 200
Study 14640934 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 alpha‐progesterone caproate (17P) 250 mg/week i.m.
Number of subjects: 0
Study 14640934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10335904 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort (D)
Number of subjects: 33
Study 10335904 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (PN)
Number of subjects: 33
Study 8747267 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal fusion for degenerative lumbar disorders
Number of subjects: 0
Study 8747267 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal fusion for recurrent disc herniation
Number of subjects: 0
Study 8747267 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal fusion for spinal stenosis and spondylolisthesis
Number of subjects: 0
Study 8747267 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal fusion for facet joint syndrome, discogenic pain, and lumbar spondylosis
Number of subjects: 0
Study 1826544 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated approach (equal attention to somatic, psychological, dietary, environmental, and physiotherapeutic factors; laparoscopy not routinely performed)
Number of subjects: 106
Study 1826544 — intervention group
Group type: COMPARATOR
Intervention: Standard approach (organic causes excluded first, routine diagnostic laparoscopy performed)
Number of subjects: 106
Study 6758831 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol 100 micrograms
Number of subjects: 12
Study 6758831 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline 250 micrograms
Number of subjects: 12
Study 31397369 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard medical treatment and human albumin (HA) infusions (40 g twice weekly for the first 2 weeks, then 40 g weekly for up to 18 months)
Number of subjects: 431
Study 31397369 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment (SMT) alone
Number of subjects: 431
Study 31397369 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard medical treatment and human albumin (HA) infusions
Number of subjects: 431
Study 26589186 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Kasai portoenterostomy (LP group)
Number of subjects: 95
Study 26589186 — intervention group
Group type: COMPARATOR
Intervention: Open Kasai portoenterostomy (OP group)
Number of subjects: 95
Study 24508841 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab in combination with gemcitabine and carboplatin (GC)
Number of subjects: 484
Study 24508841 — intervention group
Group type: COMPARATOR
Intervention: Placebo with gemcitabine and carboplatin (GC)
Number of subjects: 484
Study 22897339 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation (PVI) alone
Number of subjects: 100
Study 22897339 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex fractionated electrograms (CFAE) alone
Number of subjects: 100
Study 22897339 — intervention group
Group type: COMPARATOR
Intervention: Combined PVI + CFAE
Number of subjects: 100
Study 22897339 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of antiarrhythmic drug (AAD) in the first 3 months postablation
Number of subjects: 100
Study 22897339 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of ERAT
Number of subjects: 100
Study 22897339 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased left atrium size
Number of subjects: 100
Study 22897339 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of AAD in the first 3 months postablation
Number of subjects: 100
Study 20493783 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (OROS‐MPH) at doses of 18, 36, or 54 mg
Number of subjects: 33
Study 20493783 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 33
Study 20493783 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (OROS‐MPH)
Number of subjects: 33